Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure (Q79890392)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Hagop Kantarjian

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Susan O'Brien

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Moshe Talpaz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Gautam Borthakur

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Farhad Ravandi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Stefan Faderl

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Mary Beth Rios

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Jianqin Shan

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Francis Giles

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Jorge Cortes

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

1 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

1556-1560

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22569

7 January 2021

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22569

7 January 2021

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22569

7 January 2021

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22569

7 January 2021

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22569

7 January 2021

Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22569

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22569

7 January 2021

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22569

7 January 2021

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22569

7 January 2021

Identifiers

DOI

10.1002/CNCR.22569

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17342766%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference